[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481842":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":46,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant chemotherapy+ PD-1 antibody + radical radiotherapy","EXPERIMENTAL","All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg\u002Fm2 plus cisplatin 75 mg\u002Fm2) and camrelizumab 200 mg, followed by radical radiotherapy.",[13],"Combination Product: neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"COMBINATION_PRODUCT","neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Jie Fu, Dr","Shanghai Sixth People's Hospital, Shanghai Jiao Tong University","STUDY_CHAIR",[26],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":29},"CONTACT","8602124058972","fujie74@sjtu.edu.cn",[31],{"facility":32,"status":33,"city":34,"state":19,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Vitalbeam","RECRUITING","Shanghai","200233","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":22,"role":27,"phone":28,"phoneExt":19,"email":19},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Xiaojing Yang","Principal Investigator","100481842","phase-2-neoadjuvant-chemotherapy-combined-with-pd-1--radical-radiotherapy-in-locally-advanced-cervical-cancer-100481842",false,"NCT05554276","Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer","Neoadjuvant Chemotherapy Combined With PD-1 Antibody + Radical Radiotherapy in Unresectable Locally Advanced Cervical Cancer Patients","PD-1","Inclusion Criteria:\n\n* Patients who were pathologically diagnosed with cervical squamous cell carcinoma and were assessed as unresectable.\n\nExclusion Criteria:\n\n* Any active or present autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism)","FEMALE","18 Years","70 Years",{"count":62,"type":63},36,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.",[69,70,71,72],"Neoadjuvant Chemotherapy","PD-1 Antibody","Radiotherapy","Cervical Cancer","2024-07-24",{"date":75,"type":76},"2024-07-25","ACTUAL",{"date":78,"type":76},"2023-08-01",{"date":80,"type":63},"2025-12-31",{"name":5,"class":6},1]